Aortic & peripheral vascular disease
Antithrombotic treatment following revascularization for chronic limb-threatening ischaemia: a scientific statement of the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases and the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
Recommendations
As issued by the authors
Intensified antithrombotic treatment should be proposed in patients with chronic limb-threatening ischaemia (CLTI) following lower limb revascularization (LLR) to reduce the risk of major adverse limb events (MALE) and major adverse cardiovascular events (MACE).
Original publication
Antithrombotic treatment following revascularization for chronic limb-threatening ischaemia: a scientific statement of the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases and the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. Eur Heart J. Published 20 May 2025. doi:10.
Summarised from the published abstract; every number is checked against it